32 terminated. 32 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Terminated 32 |
| Phase 2 | 10 | Terminated 10 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio AVT16, Vedolizumab - Ulcerative Colitis | Phase 3 | Terminated | Alvotech Swiss AG | 301 | 2024-09-23 | 2025-12-26 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ozanimod, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Bristol-Myers Squibb | 131 | 2022-12-09 | 2025-03-26 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 22 | 2022-07-26 | 2024-10-04 |
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis | Phase 3 | Terminated | InDex Pharmaceuticals | 171 | 2021-11-24 | 2023-12-27 |
| Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy Valganciclovir - Ulcerative Colitis, Unspecified | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 6 | 2021-04-22 | 2024-04-10 |
| Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis Rosuvastatin 10mg - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Universitaire Ziekenhuizen KU Leuven | 177 | 2020-10-22 | 2025-11-25 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 46 | 2020-07-23 | 2022-11-02 |
| The Role of Secondary Bile Acids in Intestinal Inflammation ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis | Phase 2 / Phase 3 | Terminated | Stanford University | 2 | 2019-08-26 | 2026-03-11 |
| Efficacy & Safety of TD-1473 in Ulcerative Colitis TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 239 | 2019-03-11 | 2022-11-15 |
| Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Ontamalimab, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Shire | 380 | 2018-02-09 | 2021-06-14 |
| Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Ontamalimab, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Shire | 279 | 2017-12-05 | 2021-04-26 |
| Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC Tacrolimus, Vedolizumab, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Medical College of Wisconsin | 4 | 2017-05-18 | 2020-09-03 |
| A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) LT-02, LT-02 Placebo - Ulcerative Colitis | Phase 3 | Terminated | Prometheus Laboratories | 25 | 2016-07-01 | 2017-06-15 |
| Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis Andecaliximab, Placebo - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 165 | 2015-09-01 | 2019-04-10 |
| Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Loperamide, Placebo - Rectal Cancer, Ulcerative Colitis | Phase 3 | Terminated | Odense University Hospital | 12 | 2014-10-01 | 2016-10-11 |
| Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Etrolizumab - Ulcerative Colitis | Phase 3 | Terminated | Hoffmann-La Roche | 1822 | 2014-09-15 | 2024-10-23 |
| Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis LT-02, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Dr. Falk Pharma GmbH | 468 | 2014-07-21 | 2017-02-09 |
| Hyperbaric Oxygen for Ulcerative Colitis Hyperbaric oxygen, Sham Hyperbaric Air - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Dartmouth-Hitchcock Medical Center | 18 | 2013-08-01 | 2018-04-06 |
| HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis HMPL-004, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Hutchison Medipharma Limited | 66 | 2013-06-01 | 2020-01-13 |
| A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day - Ulcerative Colitis | Phase 3 | Terminated | Hutchison Medipharma Limited | 201 | 2013-03-01 | 2020-01-02 |
Showing 20 of 32. Sign in to see all of them.
Colitis, Ulcerative (30) · Inflammatory Bowel Diseases (7) · Gastrointestinal Diseases (4) · Colonic Diseases (3) · Ulcer (3) · Digestive System Diseases (2) · Gastroenteritis (2) · Intestinal Diseases (2) · Pathologic Processes (2) · Proctitis (2) · Proctocolitis (2) · Colitis, Lymphocytic (1) · Crohn Disease (1) · Cytomegalovirus Infections (1)
Digestive System Diseases (30) · Gastroenteritis (30) · Intestinal Diseases (30) · Colonic Diseases (29) · Gastrointestinal Diseases (28) · Inflammatory Bowel Diseases (24) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (3) · Neoplasms (2) · Rectal Diseases (2) · Behavior (1) · Colitis, Microscopic (1) · Colorectal Neoplasms (1) · DNA Virus Infections (1)
Mesalamine (3) · Andrographis paniculata extract (2) · Azathioprine (2) · Infliximab (2) · Valganciclovir (2) · ontamalimab (2) · vedolizumab (2) · visilizumab (2) · Budesonide (1) · GLPG0634 (1) · Hyperbaric Oxygenation (1) · Loperamide (1) · Prednisolone (1) · Prednisone (1) · Rosuvastatin Calcium (1)
Facet Biotech (2) · Hutchison Medipharma Limited (2) · Merck Sharp & Dohme LLC (2) · Shire (2) · Theravance Biopharma (2) · sigma-tau i.f.r. S.p.A. (2) · Alvotech Swiss AG (1) · Bausch Health Americas, Inc. (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Dartmouth-Hitchcock Medical Center (1) · Dr. Falk Pharma GmbH (1) · Forest Laboratories (1) · Gilead Sciences (1) · Hoffmann-La Roche (1)
United States (21) · France (12) · Poland (12) · Canada (11) · Germany (11) · Hungary (11) · Belgium (10) · Romania (10) · Slovakia (10) · Australia (9) · Israel (9) · Italy (9) · Ukraine (9) · Netherlands (8) · Austria (7)
Sandro Ardizzone, MD (2) · Andres J Yarur, MD (1) · Axel Dignass, MD (1) · Corey A Siegel, MD, MS (1) · Darrell S. Pardi, M.D. (1) · Eveline Schurink (1) · Gregory Gordon, M.D., J.D. (1) · Herman Ellman, MD (1)
PMID 40013523, PMID 20947884, PMID 24512909, PMID 26119226, PMID 28627732, PMID 31982148, PMID 32445184, PMID 37806372
2017 (2), 2018 (2), 2009 (1), 2014 (1), 2016 (1), 2019 (1), UL1RR024150 (1)